Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders. PERK-inhibiting compounds of Formula (I) having the following structure: are described herein. Also described herein are pharmaceutical compositions containing a compound of Formula (I) in one or more pharmaceutically acceptable carriers, diluents, or excipients, as well as methods for inhibiting a PERK enzyme in a patient or treating cancer in a patient.

Abstract: Provided herein are methods of treating advanced solid tumors in a subject in need thereof, for example, when the subject has advanced squamous cell carcinoma of the head and neck, colorectal cancer, non-small cell lung cancer, and transitional cell carcinoma of the bladder. Also provided herein are methods of treating blood cancers, such as acute myeloid leukemia, in a subject in need thereof.

Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting PERK and for treating related conditions, diseases, and disorders.

Abstract: This disclosure relates to the combination of soluble ?-glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.

Abstract: The present invention relates to the combination of soluble ?-glucan and anti-cancer agents that affect the tumor microenvironment. Soluble ?-glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: wherein A, X, Y, Z, Q, R1, R2, R3, R4, R5, and n are described herein.

Abstract: This disclosure provides, in one aspect, dosing strategies for soluble ?-glucan immunotherapy to optimize acute immunopharmacodynamic responses for the immunotherapy and/or subject. It also provides a method for analyzing a sample from a subject for a biomarker to identify the appropriate dosing strategy for soluble ?-glucan immunotherapy. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody level or immunopharmacodynamic response level, classifying the subject into a subgroup based on the biomarker anti-?-glucan antibody level or immunopharmacodynamic response level and identifying the appropriate dosing strategy based on the subgroup classification.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.

Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A1, A2, G, R1, R2, R3, R4, and W are described herein.

Abstract: This disclosure describes, in one aspect, a method for identifying ?-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble ?-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble ?-glucan to bind to the immune cells, and detecting soluble ?-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of ?-glucan, and co-administering to the subject a soluble ?-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.